Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis

Multicentre, randomized, open-label trial

Okayama Urological Research Group (OURG), Katsumi Sasaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

Original languageEnglish
Pages (from-to)529-534
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume72
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

cefditoren pivoxil
Cystitis
Safety
Fluoroquinolones
Escherichia coli
Cephalosporins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis : Multicentre, randomized, open-label trial. / Okayama Urological Research Group (OURG); Sasaki, Katsumi.

In: Journal of Antimicrobial Chemotherapy, Vol. 72, No. 2, 2017, p. 529-534.

Research output: Contribution to journalArticle

@article{efae50448ab54d51b396b8e3f41d868a,
title = "Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: Multicentre, randomized, open-label trial",
abstract = "Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7{\%} (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9{\%} (40/44) and 93.2{\%} (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5{\%} (33/40) and 90.2{\%} (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.",
author = "{Okayama Urological Research Group (OURG)} and Takuya Sadahira and Koichiro Wada and Motoo Araki and Ayano Ishii and Atsushi Takamoto and Yasuyuki Kobayashi and Masami Watanabe and Toyohiko Watanabe and Yasutomo Nasu and Hiromi Kumon and Teruaki Akaeda and Nobuyuki Akazawa and Naoki Akebi and Daiji Araki and Tohru Araki and Ryoji Arata and Yuichi Ariyoshi and Eiichi Ando and Nobuyoshi Ando and Kazushi Ishii and Tsutomu Ishikawa and Noritaka Ishito and Takaharu Ichikawa and Takaaki Inoue and Miyabi Inoue and Yosuke Inoue and Shin Irie and Takehiro Iwata and Tatsuya Uesugi and Shinya Uehara and Katsutoshi Uematsu and Satoshi Uno and Kohei Edamura and Shin Ebara and Yuko Oiwa and Tadashi Oeda and Teruhisa Ohashi and Yozo Ohashi and Hideo Ozawa and Junzo Ochi and Noriaki Ono and Seiji Kai and Haruki Kaku and Satoshi Katayama and Katsumi Sasaki and Tomoko Sako and Morito Sugimoto and Ryuta Tanimoto and Shingo Nishimura and Daisuke Yamada",
year = "2017",
doi = "10.1093/jac/dkw424",
language = "English",
volume = "72",
pages = "529--534",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis

T2 - Multicentre, randomized, open-label trial

AU - Okayama Urological Research Group (OURG)

AU - Sadahira, Takuya

AU - Wada, Koichiro

AU - Araki, Motoo

AU - Ishii, Ayano

AU - Takamoto, Atsushi

AU - Kobayashi, Yasuyuki

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Akaeda, Teruaki

AU - Akazawa, Nobuyuki

AU - Akebi, Naoki

AU - Araki, Daiji

AU - Araki, Tohru

AU - Arata, Ryoji

AU - Ariyoshi, Yuichi

AU - Ando, Eiichi

AU - Ando, Nobuyoshi

AU - Ishii, Kazushi

AU - Ishikawa, Tsutomu

AU - Ishito, Noritaka

AU - Ichikawa, Takaharu

AU - Inoue, Takaaki

AU - Inoue, Miyabi

AU - Inoue, Yosuke

AU - Irie, Shin

AU - Iwata, Takehiro

AU - Uesugi, Tatsuya

AU - Uehara, Shinya

AU - Uematsu, Katsutoshi

AU - Uno, Satoshi

AU - Edamura, Kohei

AU - Ebara, Shin

AU - Oiwa, Yuko

AU - Oeda, Tadashi

AU - Ohashi, Teruhisa

AU - Ohashi, Yozo

AU - Ozawa, Hideo

AU - Ochi, Junzo

AU - Ono, Noriaki

AU - Kai, Seiji

AU - Kaku, Haruki

AU - Katayama, Satoshi

AU - Sasaki, Katsumi

AU - Sako, Tomoko

AU - Sugimoto, Morito

AU - Tanimoto, Ryuta

AU - Nishimura, Shingo

AU - Yamada, Daisuke

PY - 2017

Y1 - 2017

N2 - Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

AB - Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

UR - http://www.scopus.com/inward/record.url?scp=85014575637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014575637&partnerID=8YFLogxK

U2 - 10.1093/jac/dkw424

DO - 10.1093/jac/dkw424

M3 - Article

VL - 72

SP - 529

EP - 534

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -